Piramal Pharma Q1 FY27: Broad-based growth lifts margins, but net profit stays in the red

Piramal Pharma Limited opened FY27 with a cleaner operational performance across all three of its businesses. Consolidated revenue from operations rose to ₹2,270 crore in Q1 FY27, up 17 percent year-on-year. EBITDA increased sharply to ₹285 crore, up 72 percent, and the EBITDA margin expanded to 12.5 percent from 8.5 percent in the same quarter last year.

The quarter, however, still ended with a consolidated net loss. Profit after tax stood at ₹(69) crore. The result highlights a familiar pattern for the company at this stage of its journey. The operating engine is improving, but depreciation, interest, and tax kept the bottom line negative.

Growth came from all three businesses

The company’s growth was broad-based. Its Contract Development and Manufacturing Organization business reported revenue of ₹1,187 crore, up 19 percent year-on-year. Complex Hospital Generics revenue grew 17 percent to ₹743 crore. Piramal Consumer Healthcare delivered 15 percent growth with revenue of ₹347 crore.

Management attributed the operating improvement to a combination of higher utilisation, operating leverage, pricing discipline, and operational excellence. The presentation also acknowledged inflationary pressure. Consumer Healthcare specifically cited raw-material inflation, which the business sought to mitigate through premiumisation, judicious pricing, and cost optimisation.

CDMO: RFP momentum, but decisions remain slow

CDMO was the largest contributor to consolidated revenue in the quarter. The company highlighted a healthy pick-up in RFPs and order inflows across multiple sites, supported by an enhanced commercial team and improved win rates.

But the presentation also pointed to a key friction point. Customer decision-making timelines remain prolonged. In other words, the funnel is active, but closure cycles remain stretched, making win-rate maintenance and RFP conversion a critical near-term variable.

The company also referenced supportive external trends. It cited industry reports showing biopharma funding in H1 CY26 was up over 100 percent compared with H1 CY25. It also pointed to geopolitical and trade uncertainties accelerating supply-chain diversification, which is driving demand for multi-site CDMO partners.

Alongside demand commentary, Piramal Pharma continued to position its integrated ADC platform as a strategic focus area. It stated that a commercial-scale payload-linker suite at Riverview in the US has been completed. It also said the Lexington sterile injectable capacity expansion remains on track, and is part of a US$90 million expansion program. The company described the Lexington additions as strengthening sterile fill-finish capability.

It also announced a partnership with Ajinomoto Bio-Pharma Services for site-specific conjugation technology under a master technology agreement, including two-way referrals and technology transfer.

Complex Hospital Generics: leadership sustained, Kenalog supply expected from Q2

Complex Hospital Generics delivered resilient growth in Q1 FY27, with revenue rising to ₹743 crore. The business continued to report leadership positions in core therapies.

In inhalation anesthesia, the company stated it retained leadership in the US Sevoflurane market with a 48 percent value share, citing IQVIA. It also noted encouraging traction across select ex-US markets.

In intrathecal therapy, it stated it maintained its number one position in the US intrathecal Baclofen market, again citing IQVIA.

A practical execution item for FY27 is Kenalog integration. The company stated integration activities are progressing and supplies are expected to start from Q2 FY27. It also noted that in injectable pain management it is working with suppliers to enhance product availability.

Consumer Healthcare: Power Brands and e-commerce carry the quarter

Consumer Healthcare continued its consistent growth profile. Revenue rose 15 percent year-on-year to ₹347 crore.

The presentation showed that Power Brands grew 23 percent year-on-year and contributed 53 percent of Consumer Healthcare sales. E-commerce grew 40 percent and contributed 28 percent of sales.

Piramal Pharma also highlighted its marketing intensity. It invested around 12 percent of Consumer Healthcare sales in media and trade promotion across digital and traditional channels.

Distribution scale was another focus point. The business reported presence across more than 180,000 chemists and cosmetic shops, more than 13,000 modern trade outlets, and over 20 e-commerce platforms. It also introduced i-choose as a master brand bringing together its women’s intimate care portfolio under a unified identity.

Why net profit stayed negative despite the margin improvement

The sharp EBITDA improvement did not translate into a positive net profit in the quarter. The consolidated P&L shows interest expense of ₹88 crore and depreciation of ₹224 crore. Profit before tax improved meaningfully to ₹(7) crore from ₹(100) crore in Q1 FY26, but remained marginally negative.

The company reported tax expense of ₹62 crore in Q1 FY27, which resulted in a net loss of ₹(69) crore.

In Q1 FY26, the reported numbers included an exceptional item of ₹21 crore. The company clarified this was linked to one-time insolvency proceeds from a claim filed against a third-party supplier for its complex hospital generics business.

Quality and operational execution remained a key theme

Piramal Pharma reiterated its focus on quality, particularly in its US manufacturing footprint. It stated the Sellersville facility received an Establishment Inspection Report from the US FDA, concluding the inspection successfully. It also stated it maintains a zero OAI track record to date.

What to track through FY27

Management’s tone in the presentation was forward-looking but measured. The Chairperson stated the company looks forward to delivering sustained revenue growth and EBITDA expansion through FY27, while staying agile amid a dynamic external environment.

For investors, three operational markers stand out from the quarter’s disclosures.

First, CDMO momentum depends on conversion, not just the volume of RFPs. The company has flagged prolonged customer timelines, which means sustained growth will likely require both win rates and improved order finalisation.

Second, Complex Hospital Generics has a clear near-term execution event. Kenalog supplies are expected to start from Q2 FY27, and progress on integration and supply continuity in other products will influence growth quality.

Third, Consumer Healthcare is scaling with meaningful brand and channel investments. The business is leaning into Power Brands, e-commerce, and premiumisation, while attempting to defend margins against raw-material inflation.

The quarter’s headline is that Piramal Pharma is showing operating leverage across a diversified portfolio. The next phase is about sustaining that momentum and moving from stronger EBITDA to durable bottom-line profitability.